News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
ErgoMed Signs Co-Development Deal With CeNeS Pharmaceuticals PLC
July 13, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ergomed today announced that it has signed a co-development deal with CeNeS Pharmaceuticals to take CNS5161, a novel NMDA antagonist, into a Phase II trial programme for neuropathic pain. Terms of the deal were not disclosed.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Earnings
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
October 30, 2026
·
4 min read
·
Heather McKenzie
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
October 30, 2026
·
2 min read
·
Nick Paul Taylor
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
October 30, 2026
·
2 min read
·
Gabrielle Masson
Earnings
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
October 30, 2026
·
3 min read
·
Annalee Armstrong
